Crypto investor Will Harbone has launched LongGame, a $40 million enterprise capital fund devoted to advancing longevity biotechnology, in keeping with a Dec. 12 assertion shared with CryptoSlate.
The initiative seeks to revolutionize human well being by extending wholesome lifespans over three a long time by way of investments in progressive fields like stem cell analysis, gene modifying, and senolytics.
LongGame targets early-stage biotech startups with scalable applied sciences, emphasizing pre-seed and seed investments. Past funding, the initiative goals to bridge biotechnology and decentralized science (DeSci), fostering collaboration between conventional life sciences and rising decentralized applied sciences.
The fund plans to combine instruments like DAOs to streamline drug discovery and encourage patient-driven analysis. Over the subsequent 4 years, LongGame intends to strategically allocate its capital whereas supporting international scalability for its portfolio corporations.
The management crew at LongGame contains COO Chloe Northcott, previously of Geometry, and Particular Advisor Sebastian A. Brunemeier, Common Associate at Healthspan Capital. Dr. Manish Chamoli, the fund’s chief scientific officer, brings deep experience in growing older biology and longevity analysis from his tenure on the Buck Institute. This crew will collaborate with specialists throughout numerous fields in medical science and biotechnology to advance its mission.
Together with his crew, Harbone envisions leveraging blockchain improvements akin to tokenization, crowdfunding, and liquidity options to handle funding gaps in longevity analysis. These mechanisms intention to democratize entry to life-extending therapies, making certain they profit a broad inhabitants somewhat than remaining unique to the rich.
He defined:
“Our purpose is to fund therapies that do extra than simply lengthen life; we’re on the lookout for options that radically increase the wholesome human lifespan—by 30 years or extra. We’re tackling the foundation causes of growing older, not simply the signs, and we wish to be sure that these life-extending therapies are accessible to the lots, not simply the rich.”
Harborne believes longevity innovation can doubtlessly disrupt international industries, very like crypto reshaped conventional finance.
In the meantime, this fund transfer aligns with a broader pattern of crypto leaders coming into the longevity area. Final 12 months, Coinbase CEO Brian Armstrong co-founded NewLimit, a biotech agency that raised $40 million to advance age-related therapies.
